Table 1.
Demographics and disease characteristics for the treated PV subset at real baseline.
| PV subset (N = 50) | |
|---|---|
| Age in years, median (range) | 59.0 (42 to 80) |
| Age group, number (%) | |
| <60 years | 25 (50.0) |
| ≥60 years | 25 (50.0) |
| Sex, number (%) | |
| Male | 31 (62.0) |
| Female | 19 (38.0) |
| Race, white, number (%) | 50 (100) |
| Time since diagnosis in years, amean ± SD | 7.2 ± 5.70 |
| Controlled hypertension, number (%) | 29 (58.0) |
| Hematology, median (range) | |
| Hemoglobin, g/l | 136 (118 to 166) |
| Hematocrit, % | 45.0 (40.9 to 50.7) |
| Platelets, 109/l | 698 (264 to 1459) |
| White blood cells, 109/l | 13.44 (3.71 to 46.48) |
| Patients requiring phlebotomy, number (%) | 47 (94.0) |
| JAK2V617F-positivity (%) | 50 (100) |
| JAK2V617F allele burden, %, median (range) | 59.75 (25.0 to 94.2) |
| Prior therapy for PV, number (%) [maximum daily dose] | |
| Antiplatelet treatments | 26 (52.0) |
| Acetylsalicylic acid | 24 (48.0) [100 mg] |
| Ticlopidine | 2 (4.0) [250 mg] |
| Clopidogrel | 1 (2.0) [75 mg] |
| Cytoreductive treatments | 30 (60.0) |
| Hydroxyurea | 24 (48.0) [1.5 g] |
| Interferon | 4 (8.0) [1.5 × 106 U] |
| Busulfan | 2 (4.0) [4 mg] |
| Number of different prior PV therapies, number (%) | |
| 0 | 11 (22.0) |
| 1 | 23 (46.0) |
| 2 | 12 (24.0) |
| 3 | 4 (8.0) |
PV polycythemia vera, JAK Janus kinase.
aAt time of entry to the long-term study.